High levels of interleukin-6 and 8-iso-prostaglandin in the exhaled breath condensate and serum of patients with chronic obstructive pulmonary disease related pulmonary hypertension

Chinese Medical Journal

Volumn 127, Issue 9, 2014, Pages 1608-1612

  He, Haiyan ^a   Tao, Yijiang ^a   Chen, Xiaoxiao ^a   Qiu, Haiyan ^a   Zhu, Jie ^a   Zhang, Jianhui ^a   Ma, Hang ^a  

^a First People's Hospital of Nantong   (China)

Author keywords

8 iso prostaglandin; Chronic obstructive pulmonary disease; Exhaled breath condensate; Interleukin 6; Pulmonary hypertension

Indexed keywords

8 ISOPROSTAGLANDIN; INTERLEUKIN 6; PROSTAGLANDIN; UNCLASSIFIED DRUG; 8-ISOPROSTAGLANDIN A2; PROSTAGLANDIN A;

AGED; ARTERIAL GAS; ARTICLE; BLOOD GAS ANALYZER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; ENZYME IMMUNOASSAY; EXPIRED AIR; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INFLAMMATION; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PLETHYSMOGRAPHY; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; BLOOD; BREATH ANALYSIS; METABOLISM; MIDDLE AGED;

AGED; BREATH TESTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSTAGLANDINS A; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84899723136     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20132502     Document Type: Article

References (23)

1. Gulsvik A. The global burden and impact of chronic obstructive pulmonary disease worldwide. Monaldi Arch Chest Dis 2001; 56: 261-264.
2. Weitzenblum E, Chaouat A, Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease. Pneumonol Alergol Pol 2013; 81: 390-398.
3. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir 2003; 21: 892-905.
4. Fabbri LM, Luppi F, Beghe B, Rabe KF. Update in chronic obstructive pulmonary disease 2005. Am J Respir Crit Care Med 2006; 173: 1056-1065.
5. Sundar IK, Yao H, Rahman I. Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases. Antioxid Redox Signal 2013; 18: 1956-1971.
6. Peterson KM, Aly A, Lerman A, Lerman LO, Rodriguez-Porcel M. Improved survival of mesenchymal stromal cell after hypoxia preconditioning: role of oxidative stress. Life Sci 2011; 88: 65-73.
7. The Global Initiative for Chronic Obstructive Lung disease (GOLD). 2010 Update: GOLD Report, Global Strategy for the Diagnosis, Management and Prevention of COPD. (Accessed at http://www.goldcopd.com)
8. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guideline for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
9. Timms RM, Khaja FU, Williams GW. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 1985; 102: 29-36.
10. Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF Jr, Lipinska I, et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008; 133: 19-25.
11. Santos S, Peinado VI, Ramírez J, Melgosa T, Roca J, Rodriguez-Roisin R, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002; 19: 632-638.
12. Peinado VI, Barbera JA, Abate P, Ramirez J, Roca J, Santos S, et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1605-1611.
13. Jiang YW, Pang L, Fang QH, Ma YM. The relationship between inflammatory mediators and pulmonary hypertension in patients with chronic obstructive pulmonary disease. Chin J Tuberc Respir 2011; 34: 904-908.
14. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22: 347-352.
15. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009; 104: 236-244.
16. Cavalcante AG, De Bruin PF. The role of oxidative stress in COPD: current concepts and perspectives. J Bras Pneumol 2009; 35: 1227-1237.
17. Janssen LJ. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1067-L1082.
18. Yi SL, Kantores C, Belcastro R, Cabacungan J, Tanswell AK, Jankov RP. 8-Isoprostane-induced endothelin-1 production by infant rat pulmonary artery smooth muscle cells is mediated by Rho-kinase. Free Radic Biol Med 2006; 41: 942-949.
19. Delannoy E, Courtois A, Freund-Michel V, Leblais V, Marthan R, Muller B. Hypoxia-induced hyperreactivity of pulmonary arteries: role of cyclooxygenase-2, isoprostanes, and thromboxane receptors. Cardiovasc Res 2010; 85: 582-592.
20. Montuschi P. Analysis of exhaled breath condensate in respiratory medicine methodological and potential clinical applications. Ther Adv Respir Dis 2007; l: 5-23.
21. Sun Y, Wang XM, Chen YH, Zhu RX, Liao CC. Exhaled hydrogen sulfide in patients with chronic obstructive pulmonary disease and its correlation with exhaled nitric oxide. Chin Med J 2013; 126: 3240-3244.
22. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56: 515-548.
23. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28: 219-242.